Core Viewpoint - Gujing Gongjiu's stock price has experienced a decline of 10.72% year-to-date, with a recent drop of 2.00% on October 29, 2023, indicating potential challenges in the market [1] Financial Performance - For the first half of 2025, Gujing Gongjiu reported revenue of 13.88 billion yuan, a year-on-year increase of 0.54%, and a net profit attributable to shareholders of 3.66 billion yuan, up 2.49% year-on-year [2] - Cumulatively, the company has distributed 12.61 billion yuan in dividends since its A-share listing, with 7.14 billion yuan distributed over the past three years [3] Shareholder Information - As of October 10, 2023, the number of shareholders increased to 50,400, reflecting a growth of 1.99% [2] - The top circulating shareholders include major funds, with notable changes in holdings, such as an increase of 1.80 million shares by the second-largest shareholder, while others like the eighth-largest shareholder reduced their holdings by 1.85 million shares [3] Market Activity - On October 29, 2023, Gujing Gongjiu's stock traded at 149.37 yuan per share, with a total market capitalization of 78.96 billion yuan [1] - The stock has seen a trading volume of 181 million yuan, with a turnover rate of 0.29% [1]

Core Viewpoint - Anjiasi's stock has experienced a decline recently, with a notable drop in trading volume and a mixed performance in revenue and profit growth [1][2]. Company Overview - Anjiasi Medical Technology Co., Ltd. was established on December 6, 2010, and went public on May 19, 2023. The company is based in Hangzhou, Zhejiang Province, and specializes in the research, development, production, and sales of minimally invasive diagnostic and therapeutic instruments [1]. - The main business revenue composition is as follows: GI category 62.74%, EMR/ESD category 23.26%, ERCP category 11.04%, instruments category 2.21%, and others 0.74% [1]. Financial Performance - For the period from January to September 2025, Anjiasi achieved operating revenue of 459 million yuan, representing a year-on-year growth of 7.51%. However, the net profit attributable to the parent company was 177 million yuan, showing a year-on-year decrease of 10.35% [2]. - Since its A-share listing, Anjiasi has distributed a total of 239 million yuan in dividends [3]. Shareholder Information - As of October 20, 2025, the number of shareholders for Anjiasi was 5,728, an increase of 2.89% from the previous period. The average circulating shares per person decreased by 2.47% to 7,255 shares [2]. - Notable new institutional shareholders include Ping An Low Carbon Economy Mixed A (009878) as the fourth largest shareholder with 850,000 shares, and Hong Kong Central Clearing Limited as the eighth largest shareholder with 420,900 shares [3].

Core Insights - Chengdu Bank reported a revenue of 17.761 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 3.01% [1] - The net profit attributable to shareholders reached 9.493 billion yuan, with a year-on-year increase of 5.03% [1] - The basic earnings per share stood at 2.24 yuan [2] Financial Performance - The bank's gross profit margin was 63.40%, an increase of 1.64 percentage points year-on-year [2] - The net profit margin was 53.45%, up by 1.02 percentage points compared to the same period last year [2] - The weighted average return on equity was 11.40% [2] Market Valuation - As of October 28, the price-to-earnings ratio (TTM) was approximately 5.77 times, and the price-to-book ratio (LF) was about 0.87 times [2] - The price-to-sales ratio (TTM) was around 3.24 times [2] Shareholder Structure - By the end of Q3 2025, the total number of shareholders was 53,400, an increase of 8,781 or 19.69% from the end of the previous half [2] - The average market value of shares held per shareholder decreased from 1.9102 million yuan to 1.3697 million yuan, a decline of 28.30% [2] Company Overview - Chengdu Bank is located at 16 Xiyu Street, Chengdu, Sichuan Province, and was established on May 8, 1997 [2] - The bank was listed on January 31, 2018, and its main business includes corporate banking, personal banking, and funding operations [2] - Chengdu Bank is classified under the banking sector as a city commercial bank and is associated with concepts such as undervalued stocks, low P/E ratios, value growth, MSCI China, and high dividends [2]

Core Viewpoint - Fuyao Glass has shown a positive stock performance with a year-to-date increase of 14.87% and a recent rise of 2.01% on October 27, 2023, indicating strong market interest and financial health [1][2]. Financial Performance - For the period from January to September 2025, Fuyao Glass reported a revenue of 33.302 billion yuan, representing a year-on-year growth of 17.62%, and a net profit attributable to shareholders of 7.064 billion yuan, which is an increase of 28.93% compared to the previous year [2]. - The company has distributed a total of 35.683 billion yuan in dividends since its A-share listing, with 13.701 billion yuan distributed over the last three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Fuyao Glass decreased to 85,700, a reduction of 8.07% from the previous period, while the average number of circulating shares per person increased by 8.79% to 23,375 shares [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 398 million shares, which increased by 24.511 million shares from the previous period [3]. Stock Market Activity - On October 27, 2023, Fuyao Glass's stock price was 68.58 yuan per share, with a trading volume of 583 million yuan and a turnover rate of 0.43%, leading to a total market capitalization of 178.976 billion yuan [1]. - The stock has experienced a 4.59% increase over the last five trading days, a 4.02% decrease over the last 20 days, and a 22.71% increase over the last 60 days [1]. Business Overview - Fuyao Glass specializes in the design, production, and sales of automotive-grade float glass and automotive glass, with its main business revenue composition being 91.10% from automotive glass, 14.43% from float glass, and 10.51% from other sources [1]. - The company is categorized under the automotive industry, specifically in automotive parts and body accessories, and is associated with various concept sectors including special glass and automotive components [1].

Core Viewpoint - Jiangsu Jinzu's stock price has shown a significant increase this year, with a 24.04% rise, indicating strong market performance and investor interest [1][2]. Group 1: Stock Performance - As of October 27, Jiangsu Jinzu's stock price rose by 2.16% to 6.14 CNY per share, with a trading volume of 1.21 billion CNY and a market capitalization of 35.565 billion CNY [1]. - The stock has experienced a 5.14% increase over the last five trading days, an 11.03% increase over the last 20 days, and a 3.19% increase over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Jiangsu Jinzu reported a net profit of 2.446 billion CNY, reflecting a year-on-year growth of 9.82% [2]. - The company has distributed a total of 7.637 billion CNY in dividends since its A-share listing, with 4.023 billion CNY distributed in the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, Jiangsu Jinzu had 59,000 shareholders, an increase of 10.98% from the previous period, with an average of 98,106 shares held per shareholder, a decrease of 9.88% [2]. - The top ten circulating shareholders include notable funds, with Huatai-PB SSE Dividend ETF holding 73.574 million shares, an increase of 4.088 million shares from the previous period [3].

Core Viewpoint - Zhaoli Pharmaceutical's stock has shown a year-to-date increase of 25.88%, with a recent market capitalization of 13.039 billion yuan, indicating positive market sentiment and growth potential in the pharmaceutical sector [1]. Financial Performance - For the first half of 2025, Zhaoli Pharmaceutical reported a revenue of 1.599 billion yuan, reflecting a year-on-year growth of 11.99%, and a net profit attributable to shareholders of 374 million yuan, which is a 26.16% increase compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 1.442 billion yuan, with 942 million yuan distributed over the last three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 38,600, with an average of 15,627 circulating shares per shareholder, a slight decrease of 0.91% [2]. - New institutional shareholders include China Europe Responsibility Investment Mixed A and Innovation Medicine, both entering the top ten circulating shareholders [3]. Stock Performance - As of October 27, Zhaoli Pharmaceutical's stock price was 18.59 yuan per share, with a trading volume of 134 million yuan and a turnover rate of 1.22% [1]. - The stock has experienced a slight increase of 0.43% over the last five trading days and a 5.39% increase over the last 20 days, while showing a minor decline of 0.48% over the past 60 days [1]. Business Overview - Zhaoli Pharmaceutical, established on January 28, 2000, specializes in the research, production, and sales of medicinal fungi, traditional Chinese medicine pieces, and formula granules, with the main revenue sources being the Wuling series (56.07%) and traditional Chinese medicine pieces (21.85%) [1]. - The company operates within the pharmaceutical and biotechnology sector, focusing on traditional Chinese medicine and related concepts such as gene sequencing and pharmaceutical e-commerce [1].

Core Viewpoint - Ningbo Bank's stock price has shown a positive trend, with a year-to-date increase of 19.82% and a market capitalization of 185.23 billion yuan as of October 23 [1] Financial Performance - For the first half of 2025, Ningbo Bank reported a net profit attributable to shareholders of 14.77 billion yuan, representing a year-on-year growth of 8.23% [2] - The company has cumulatively distributed dividends of 35.80 billion yuan since its A-share listing, with 13.21 billion yuan distributed in the last three years [3] Stock Market Activity - As of October 23, Ningbo Bank's stock price was 28.05 yuan per share, with a trading volume of 9.23 billion yuan and a turnover rate of 0.50% [1] - The stock experienced a net inflow of 34.60 million yuan from main funds, with significant buying activity from large orders [1] Shareholder Information - As of June 30, 2025, Ningbo Bank had 102,600 shareholders, a decrease of 2.31% from the previous period, with an average of 64,343 circulating shares per shareholder, an increase of 3.56% [2] - Hong Kong Central Clearing Limited is the fourth-largest circulating shareholder, holding 249 million shares, a decrease of 5.08 million shares from the previous period [3] Business Overview - Ningbo Bank's main business segments include public deposit acceptance (42.24%), fund business (29.21%), personal business (27.81%), and other services (0.73%) [1]

Company Overview - Anjess Medical Technology Co., Ltd. is located in Hangzhou, Zhejiang Province, established on December 6, 2010, and listed on May 19, 2023 [1] - The company specializes in the research, production, and sales of minimally invasive diagnostic and therapeutic instruments, with main business revenue composition as follows: GI category 62.74%, EMR/ESD category 23.26%, ERCP category 11.04%, instruments category 2.21%, and others 0.74% [1] Stock Performance - As of October 23, Anjess's stock price decreased by 2.12%, trading at 64.52 CNY per share, with a total market capitalization of 5.234 billion CNY [1] - Year-to-date, the stock price has increased by 10.64%, but it has declined by 3.69% over the last five trading days, 12.36% over the last twenty days, and 10.61% over the last sixty days [1] Financial Performance - For the first half of 2025, Anjess achieved operating revenue of 302 million CNY, representing a year-on-year growth of 14.56%, and a net profit attributable to shareholders of 126 million CNY, with a year-on-year growth of 1.26% [2] - Since its A-share listing, Anjess has distributed a total of 239 million CNY in dividends [3] Shareholder Information - As of October 20, the number of shareholders for Anjess was 5,728, an increase of 2.89% from the previous period, with an average of 7,255 circulating shares per shareholder, a decrease of 2.47% [2] - As of June 30, 2025, Hong Kong Central Clearing Limited exited the list of the top ten circulating shareholders [3]

Core Points - Qingdao Bank's stock price increased by 2.12% on October 23, reaching 5.29 CNY per share, with a total market capitalization of 30.79 billion CNY [1] - The bank's stock has risen 42.20% year-to-date, with a 6.01% increase over the last five trading days [1] Financial Performance - As of June 30, Qingdao Bank reported a net profit attributable to shareholders of 3.065 billion CNY, representing a year-on-year growth of 16.05% [2] - The bank's cumulative cash dividends since its A-share listing amount to 6.341 billion CNY, with 2.794 billion CNY distributed over the past three years [3] Shareholder Information - The number of shareholders increased to 51,100, a rise of 0.51% compared to the previous period, while the average number of circulating shares per person decreased by 0.50% to 61,038 shares [2] Business Overview - Qingdao Bank, established on November 15, 1996, and listed on January 16, 2019, operates primarily in corporate banking (47.29%), financial market business (26.27%), and retail banking (21.87%) [1]

Core Viewpoint - The stock of TEBIO experienced a decline of 2.02% on October 22, 2023, with a current price of 76.96 CNY per share and a market capitalization of 31.307 billion CNY [1] Financial Performance - For the first half of 2025, TEBIO reported a revenue of 1.511 billion CNY, representing a year-on-year growth of 26.96%, and a net profit attributable to shareholders of 428 million CNY, which is a 40.60% increase compared to the previous year [2] Shareholder Information - As of June 30, 2025, TEBIO had 8,439 shareholders, an increase of 13% from the previous period, with an average of 48,204 circulating shares per shareholder, down by 11.51% [2] - The company has distributed a total of 577 million CNY in dividends since its A-share listing, with 506 million CNY distributed over the past three years [3] Stock Trading Activity - On October 22, 2023, TEBIO saw a net inflow of 8.826 million CNY from main funds, with significant buying and selling activity from large orders [1]